



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 897 002 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
04.10.2001 Bulletin 2001/40

(51) Int Cl.⁷: **C12N 15/12, C07K 14/47,
C07K 16/18, A61K 38/17,
C12Q 1/68, G01N 33/68**

(43) Date of publication A2:
17.02.1999 Bulletin 1999/07

(21) Application number: **98305494.1**

(22) Date of filing: **10.07.1998**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **14.08.1997 EP 97306180**

(71) Applicant: **SMITHKLINE BEECHAM PLC
Brentford, Middlesex TW8 9EP (GB)**

(72) Inventor: **Michalovich, David,
SmithKline Beecham Pharm.
Harlow, Essex CM19 5AW (GB)**

(74) Representative: **Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)**

(54) **U62317, a protein having a JNK-binding domain**

(57) The use of U623 17 polypeptides and polynucleotides in the design of protocols for the treatment of cancer, developmental disorders, myeloid leukemia, im-

mune disorders and neurodegenerative diseases, among others, and diagnostic assays for such conditions. Also disclosed are methods for producing such polypeptides by recombinant techniques.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|---|--|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.6) |
| D, X | <p>DATABASE EMBL 'Online! Acc. No. HS384D8, 12 July 1996 (1996-07-12) ADAMS ET AL.: "U62317 Homo sapiens chromosome" XP002173754</p> <p>---</p> | 1-5,8,11 | C12N15/12 C07K14/47 C07K16/18 A61K38/17 C12Q1/68 G01N33/68 |
| X | <p>DATABASE EMBL 'Online! Acc. No. HSU79261, 14 December 1996 (1996-12-14) ANDERSSON ET AL.: "Human clone 23959 mRNA" XP002173671</p> <p>---</p> | 1-5,8,11 | |
| X | <p>DATABASE EMBL 'Online! Acc. No. Q13387, 1 November 1996 (1996-11-01) ADAMS, M.D.: "Hypothetical protein 384D8_2" XP002173672</p> <p>---</p> <p>---</p> | 1-5,8,11 | |
| | | -/- | |
| INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p> | | | |
| Place of search | | Date of completion of the search | Examiner |
| MUNICH | | 2 August 2001 | Niebuhr-Ebel, K |
| CATEGORY OF CITED DOCUMENTS | | | |
| X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | |



European Patent
Office

**INCOMPLETE SEARCH
SHEET C**

Application Number
EP 98 30 5494

Claim(s) searched completely:
1-5, 8, 9, 11

Claim(s) not searched:
6, 7, 10

Reason for the limitation of the search:

Claim 10 is directed to an agonist or antagonist of the U62317 polypeptide, but in the description no examples for a specific agonist or antagonist are given. As the subject-matter is solely defined by the method of its identification (claim 9), the scope of the claim remains completely unclear and too broad. In addition, it leaves the possibility that the compounds identified in claim 9 are already known in the art and are therefore not novel.

Claims 6 and 7 are directed to methods of treatment including the therapeutic administration of a U62317 agonist / antagonist. As these claims make use of said completely undefined compounds, the scope of the claims is unclear for same the reasons as given above.

This lack of clarity renders a meaningful search for claims 6, 7 and 10 impossible, and consequently the search has been restricted to claims 1-5. 8, 9, and 11.



| DOCUMENTS CONSIDERED TO BE RELEVANT | | | CLASSIFICATION OF THE APPLICATION (Int.Cl.6) |
|-------------------------------------|---|-------------------|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | |
| D, X | <p>DICKENS M ET AL: "A cytoplasmic inhibitor of the JNK signal transduction pathway" SCIENCE, US, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, no. 277, 1 August 1997 (1997-08-01), pages 693-696, XP002076860 ISSN: 0036-8075 *abstract* * page 695, column 3, last paragraph – page 696, column 1, last paragraph *</p> <p>GUPTA S ET AL: "SELECTIVE INTERACTION OF JNK PROTEIN KINASE ISOFORMS WITH TRANSCRIPTION FACTORS" EMBO JOURNAL, GB, OXFORD UNIVERSITY PRESS, SURREY, vol. 15, no. 11, 1996, pages 2760-2770, XP002915477 ISSN: 0261-4189 * Materials and methods * * page 2767, right-hand column, last paragraph – page 2768, left-hand column, paragraph 1 *</p> | 9 | |
| A | | 9 | TECHNICAL FIELDS SEARCHED (Int.Cl.6) |